Express Scripts faces three subpoenas over dealings with drugmakers

1 May 2014

US pharmacy benefits manager Express Scripts has revealed that it has received three government subpoenas since February regarding its dealings with USA and European drugmakers.

After it announced its first quarter results on Tuesday, the company said that it had received subpoenas from federal prosecutors in Rhode Island, from the Attorney General of New Jersey and from the US Department of Labor, according to Reuters.

In a conference call chief executive George Paz said: “I tell you we have very strong compliance programs here at Express Scripts, so I don't know where all these things take us or what they are looking for. But I feel good about what we do, so we will just have to see how these things play out.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK